Remove Adverse Reactions Remove Clinic Management Remove FDA
article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

Despite advancements in treatment, certain patients may exhibit delayed responses, have drug-resistant TB, be at risk for drug-drug interactions, or have comorbid conditions that considerably complicate clinical management. In 2014, the US FDA approved this regimen, and it features in the latest WHO guidelines for LTBI treatment.